What Happened?
Cambridge, MA-based C4-Therapeutics Appointed Jason Fisherman as Chief Executive Officer
About the Company
C4 Therapeutics is pioneering a new class of drugs. C4`s technology platform produces small molecule drugs that harness machinery already present in cells to selectively target disease-relevant proteins for degradation. Our approach has the potential to address a broad range of diseases including cancer, infectious disease, and autoimmune disorders.
About the Person
Dr. Jason S. Fisherman, M.D., MBA has been Chief Executive Officer and President at C4 Therapeutics, Inc. since January 7, 2016. Dr. Fisherman Co-Founded Synthesis Capital in 2007 and has been its Managing Director since 2007. He focuses on healthcare, information technologies, biopharmaceuticals, life science, biopharmaceutical, and medical technology industries. Dr. Fisherman serves as the Managing Director of White Cube Management, which he joined in 2007. From 1994 to 2007, he was at the Advent International and its Managing Director since 2002. Dr. Fisherman served as Managing Director at Advent Health Care & Life Sciences III, L.P., Advent Health Care & Life Sciences II, L.P. and Advent Health Care & Life Sciences I, L.P. Dr. Fisherman began his career in venture capital in 1994 and has focused on healthcare and life science investing for the past 18 years. Dr. Fisherman co-founded Advent Healthcare Ventures in 2007, where he focused on biopharmaceuticals and medical information technologies. He served as Vice President and a Partner of Advent International Corporation. He served as Senior Director of Medical Research of Enzon Pharmaceuticals Inc. from 1991 to 1994. While a research fellow at Dana Farber Cancer Institute, he focused on the regulation of gene transcription and molecular oncology. Prior to joining Advent International, Dr. Fisherman had over ten years of drug research and clinical development experience in biotechnology, academia and the National Cancer Institute. He has focused on healthcare and life science investing for the past 20 years. He served as the Chairman of Spherics, Inc. Dr. Fisherman served as Chairman of Anadys Pharmaceuticals Inc. from July 2000 to December 31, 2005. Dr. Fisher has been a Director of Trident Pharmaceuticals, Inc., since June, 2012. He serves as Director for Cellzome AG. He has been a Director of Achillion Pharmaceuticals, Inc. since March 2000 and C4 Therapeutics, Inc. since January 7, 2016. He serves as a Director of Ampla Pharmaceuticals, MDeverywhere, Inc., Spear Therapeutics, and Physician`s Online, LLC. He has been a Director of Nereus Pharmaceuticals Inc. since May 12, 2005. He serves as a Director of Prexa Pharmaceuticals, Inc. He serves as a Director of Neurogenetics Inc., Oridon Systems Ltd., Med e-Manager Corp., IntroGene BV, Managed Healthcare Associates Inc. and several private companies. Dr. Fisherman has been a Member of Clinical & Scientific Advisory Board of Anadys Pharmaceuticals Inc. since December 31, 2005. He served as a Director of ILEX Oncology Inc. since September 1995 and as a Director of TPTX Inc., a subsidiary of TorreyPines Therapeutics, Inc. from May 2000 to February 2007. Dr. Fisherman served as a Director of Oridion Systems Ltd. He also served as Director of Aegerion Pharmaceuticals, Inc., from December 2005 to April 12, 2011. He also served as a Director of Torreypines Therapeutics Inc. from October 2006 to June 12, 2009. He was a Director of Exelixis, Inc. from March 1996 to December 31, 2004 and Physician`s Online, LLC. He served as a Director of Anadys Pharmaceuticals Inc. from March 1996 to December 31, 2005 and Raptor Pharmaceuticals Corp. until June 12, 2009. Dr. Fisherman served as a Director of Mediconsult.com, Inc. since 1999. He served as a Director of Spherics, Inc. Dr. Fisherman served as a Member of Supervisory Board of Crucell NV. A medical oncologist by training, he serves on the Visit Committee at the Dana Farber Cancer Institute. He is Board Certified in Internal Medicine and Medical Oncology. Dr. Fisherman`s qualifications include his scientific experience, notably in clinical development and strategic product development with experience in areas such as financing, business development and alliance formation. Dr. Fisherman holds an M.D. from the University of Pennsylvania, an M.B.A. degree from Wharton Graduate School of Business of the University of Pennsylvania, and a B.A. degree in Molecular Biophysics and Biochemistry from Yale University.
Info Source
Press Release
Short Profile